$PEMTF Looks to Capitalize on the Lucrative Shroom Boom
Thoughtful Brands Inc. (PEMTF)
Canada (MOTA.CN) Germany (5SO.F).
Alert Price: $0.15
Float: 145.17
Thoughtful Brands, Inc. (PEMTF) looks like one of the hottest undetected CBD players around and could soon hit the spotlight as company looks to capitalize on the lucrative Shroom Boom too!
CBD has become one of the most talked about topics on Wall Street, in the media, and among consumers.
It could become the wellness routine of many Americans and people in the world as more consumers recognize the health benefits of the marijuana compound. The cannabinoid is set to help with anxiety, insomnia, aches and pains, and a long list of other things.
A Gallup survey has found that 1 in 7 adults are now using CBD products!
After cannabis, the next big boom could be psilocybin, or better known as medicinal mushrooms!
Many are suddenly asking if shrooms will be the next big thing in plant medicine.
Several clinical trials in the last half-decade have concluded that psilocybin can effectively treat anxiety, depression, and other conditions.
The federal government is now seriously considering legalizing this natural psychedelic as an adjunct to therapy.
Finding the right CBD and psilocybin opportunities on Wall Street could be the ticket to monster profits!
PEMTF is a company focusing on both and may not be flying under the radar much longer!
About the Company:
Thoughtful Brands, Inc. (PEMTF) is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe.
The company is involved with the development and sale of natural health products through its eCommerce technology, with a focus on the CBD and psychedelic medicine sectors.
In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature's Exclusive brand.
Within Europe, PEMTF’s Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.
The company is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products.
The Company has acquired Verrian, a leading company in the psychedelic medicine sector.
Verrian is an Established European Psychedelic Medicine Company!
Verrian owns and operates a 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.
Verrian is composed of three distinct business segments:
Pharmaceutical Manufacturing - A portfolio of medical & wellness products
Phyto API - API creation from medical plants
Analytical Testing - European Medicine Agency Standards
Products Focused On Opiate Addiction Reductions
Verrian's singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.
The company's product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs.
All of Verrian's compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes
While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids.
For those individuals who have suffered a loss due to one's addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Thoughtful Brands, Inc. (PEMTF) is even more meaningful.
In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients.
According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42 million in 2020, with over 15,000 private treatment facilities and growing.
Verrian's product commercialization process is already underway. The business has invested over C$2 million in clinical trials with two studies that are ongoing. These studies combined with the company's manufacturing abilities will uniquely prepare them to go-to-market once approval is granted.
Huge Revenue Opportunity With Nature's Exclusive
PEMTF’s Natures Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer.
The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer.
Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CDB skin serum and CBD coffee.
The brand, which provides CBD products to consumers in the US and Europe, clocked up revenue of C$29 million last year!
The company has launched a CBD hand sanitizer with 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E. It is initially offered only to consumers in the United States.
In order to differentiate the Company's hand sanitizer offering within this crowded space, PEMTF has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD.
This ability to formulate and innovate new products of this caliber is a direct result of the Company's strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil.
The coronavirus has changed the behavior of many. More people are now actively looking for ways to protect themselves from germs while in public and hand sanitizer has become a staple.
The pressing need for hand sanitizer could continue to go on even when the pandemic is over!
According to Research and Markets, hand sanitizer sales are expected to reach more than $3.043 million by the year 2027, which is up from $1.106 million in 2018. This is a projected growth rate of 11.9 percent.
PEMTF's Nature's Exclusive Brand Sees Record Revenues and Monster Subscriber Growth
Results of the 2019 calendar year audit of the company's Nature's Exclusive brand found:
Revenue of C$29,034,000
Net income of C$3,505,000
Achieved a margin of over 12%
The 2019 financial results for the Nature's Exclusive brand are a strong indicator of the power of the PEMTF's eCommerce business model.
This growth continued into 2020.
For the months January through April 2020, the Company had generated revenue of C$13,968,000 with related expenses of C$13,514,000. Revenue has increased 188% for this time period over the same period during 2019!
The company announced record revenues for the month of April totaling C$3,818,000, representing an increase of 39% compared to April 2019. Expenses totaled C$3,609,000, representing a Gross Profit of C$209,000 for the month.
For the first quarter, the company reported C$7.65M in revenue!
Consolidated Q1 2020 gross revenue was C$7.65 million, with cost of goods sold of C$7.05 million, resulting in gross profits of C$605,150. Operating and other operating expenses for the three months ended March 31, 2020 were C$5.24 million.
The Company raised C$1.72 million through share subscriptions received for the issuance of units at C$0.28 and received C$309,000 in proceeds from the exercise of warrants.
The Company ended Q1 2020 with C$2.1 million in cash.
Dominant Online Customer Acquisition Strategy
The Company credits its success to its’ online customer acquisition strategy, which is capitalizing on the strong consumer demand for natural health solutions, resulting in an interim record number of customer acquisitions for the Nature’s Exclusive brand, as well as, new customers for the immune support category introduced in March 2020.
The Company's customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature's Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.
The company said it plans to follow a similar rollout strategy as it did in the US market in Europe.
PEMTF acquired 102,844 new customers during the six-month period ending June 30, 2020.
This record number of customers acquired can be attributed to the Company's increased marketing efforts of its Nature's Exclusive brand, as well as a successful scaling of the Company's supply chain, and its ability to respond to market demand in the midst of a global pandemic through the introduction of new and relevant products.
Market Outlook:
“The hemp-CBD market alone is estimated to hit $22 billion by 2022.”
– The Brightfield Group
Boomers and millennials alike are buzzing about three letters - CBD.
CBD has become very popular in recent years and is considered one of the hottest new health and wellness trends.
It is a natural compound found in cannabis and hemp and does not cause a high like the compound THC. Changes to state and federal laws have led to a rise in the production of CBD-infused products.
More and more consumers are realizing the medicinal benefits of this cannabidiol.
CBD oil is said to treat a wide variety of health problems, including: pain, epileptic seizures, anxiety disorders and depression, insomnia, stress, skin conditions, etc.
According to Grand View Research, by 2027, adult-use medicinal cannabis is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.
35% of U.S. adults say they are not familiar with CBD, while another 50% say they are aware of it but do not use it.
Do you know what this means? It means there is still a significant chunk of America that could be on its way to using CBD. The market potential is a monster.
Hemp CBD is one of the fastest-growing markets in a generation with sales projected to reach into the billions. The Hemp Business Journal has predicted that the market for CBD will grow from $390 million in 2018 to approximately $1.3 billion by 2022.
CBD is seeing monumental demand in Europe!
In Europe alone, the CBD market is on course to grow 400% over the next four years, according to the Brightfield Group.
According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.
THE PSYCHEDELIC MEDICINE OPPORTUNITY
The new buzzed topic is psychedelic medicine and this "mush rush" ... this "shroom boom" could send early players in the space soaring.
Psilocybin, or better known as medicinal mushrooms, could be the key to treating many mental disorders in the world. This includes depression, anxiety, and even addiction.
Can you imagine big pharma jumping all over this?
GW Pharmaceuticals not long ago became well known for its popular cannabidiol (CBD)-based drug, Epidiolex. It is the first FDA approved medication made from cannabis and has produced millions upon millions in revenue for the company.
Magic mushrooms in fact are the safest “recreational” drug to take and those who take them are the most sensible and well prepared, according to the 2017 Global Drug Survey.
Out of almost 10,000 people who took them, only 0.2% needed emergency medical treatment.
Ongoing clinical trials are discovering the uses of psilocybin in the treatment of addiction and other mental health problems.
Johns Hopkins University is the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.
Its publication on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide!
The University began clinical trials on the potential positive effects of the drug when it comes to aiding treatment-averse depression, addiction, and anxiety.
The results were so promising that the institution published an article arguing that psilocybin should be considered a Schedule 5 drug!
At the Center for Psychedelic and Consciousness Research, researchers will now focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health.
Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use in people with major depression.
Recent Developments:
Thoughtful Brands Aquires E-Commerce Platform That Has Facilitated Over $200 Million in Consumer Transactions
Thoughtful Brands Enters into Letters of Intent to Consider Acquisitions of Golden Path and Wild Mariposa
The Bottom Line:
PEMTF is trading at mere pennies yet has a narrative that reads like a big board story.
Just look at some comparatives in the arena to see what substantial growth potential the company has:
The company is poised to take its winning model from America to Europe and is aiming to become a CBD leader on two continents!
An entrance into the psilocybin space could also be a massive opportunity for the company to capitalize on the Mush Rush. Medicinal mushrooms could be the key to treating depression, anxiety, addiction, and even Alzheimer's Disease.
Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.
As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.
At these share prices PEMTF may be a ground-floor situation to keep a close eye on!
PEMTF may be one of 2020's biggest secrets trading on Wall Street headed towards major recognition soon!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
Canada (MOTA.CN) Germany (5SO.F).
Alert Price: $0.15
Float: 145.17
Thoughtful Brands, Inc. (PEMTF) looks like one of the hottest undetected CBD players around and could soon hit the spotlight as company looks to capitalize on the lucrative Shroom Boom too!
CBD has become one of the most talked about topics on Wall Street, in the media, and among consumers.
It could become the wellness routine of many Americans and people in the world as more consumers recognize the health benefits of the marijuana compound. The cannabinoid is set to help with anxiety, insomnia, aches and pains, and a long list of other things.
A Gallup survey has found that 1 in 7 adults are now using CBD products!
After cannabis, the next big boom could be psilocybin, or better known as medicinal mushrooms!
Many are suddenly asking if shrooms will be the next big thing in plant medicine.
Several clinical trials in the last half-decade have concluded that psilocybin can effectively treat anxiety, depression, and other conditions.
The federal government is now seriously considering legalizing this natural psychedelic as an adjunct to therapy.
Finding the right CBD and psilocybin opportunities on Wall Street could be the ticket to monster profits!
PEMTF is a company focusing on both and may not be flying under the radar much longer!
About the Company:
Thoughtful Brands, Inc. (PEMTF) is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe.
The company is involved with the development and sale of natural health products through its eCommerce technology, with a focus on the CBD and psychedelic medicine sectors.
In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature's Exclusive brand.
Within Europe, PEMTF’s Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.
The company is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products.
The Company has acquired Verrian, a leading company in the psychedelic medicine sector.
Verrian is an Established European Psychedelic Medicine Company!
Verrian owns and operates a 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.
Verrian is composed of three distinct business segments:
Pharmaceutical Manufacturing - A portfolio of medical & wellness products
Phyto API - API creation from medical plants
Analytical Testing - European Medicine Agency Standards
Products Focused On Opiate Addiction Reductions
Verrian's singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.
The company's product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs.
All of Verrian's compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes
While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids.
For those individuals who have suffered a loss due to one's addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Thoughtful Brands, Inc. (PEMTF) is even more meaningful.
In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients.
According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42 million in 2020, with over 15,000 private treatment facilities and growing.
Verrian's product commercialization process is already underway. The business has invested over C$2 million in clinical trials with two studies that are ongoing. These studies combined with the company's manufacturing abilities will uniquely prepare them to go-to-market once approval is granted.
Huge Revenue Opportunity With Nature's Exclusive
PEMTF’s Natures Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer.
The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer.
Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CDB skin serum and CBD coffee.
The brand, which provides CBD products to consumers in the US and Europe, clocked up revenue of C$29 million last year!
The company has launched a CBD hand sanitizer with 70% ethyl alcohol as its active ingredient, as well as, CBD isolate and Vitamin E. It is initially offered only to consumers in the United States.
In order to differentiate the Company's hand sanitizer offering within this crowded space, PEMTF has formulated a product that is specifically designed for its target consumers by combining the antimicrobial properties of ethyl alcohol with the benefits of CBD.
This ability to formulate and innovate new products of this caliber is a direct result of the Company's strong supply chain, which has continued to operate uninterrupted despite the recent worldwide turmoil.
The coronavirus has changed the behavior of many. More people are now actively looking for ways to protect themselves from germs while in public and hand sanitizer has become a staple.
The pressing need for hand sanitizer could continue to go on even when the pandemic is over!
According to Research and Markets, hand sanitizer sales are expected to reach more than $3.043 million by the year 2027, which is up from $1.106 million in 2018. This is a projected growth rate of 11.9 percent.
PEMTF's Nature's Exclusive Brand Sees Record Revenues and Monster Subscriber Growth
Results of the 2019 calendar year audit of the company's Nature's Exclusive brand found:
Revenue of C$29,034,000
Net income of C$3,505,000
Achieved a margin of over 12%
The 2019 financial results for the Nature's Exclusive brand are a strong indicator of the power of the PEMTF's eCommerce business model.
This growth continued into 2020.
For the months January through April 2020, the Company had generated revenue of C$13,968,000 with related expenses of C$13,514,000. Revenue has increased 188% for this time period over the same period during 2019!
The company announced record revenues for the month of April totaling C$3,818,000, representing an increase of 39% compared to April 2019. Expenses totaled C$3,609,000, representing a Gross Profit of C$209,000 for the month.
For the first quarter, the company reported C$7.65M in revenue!
Consolidated Q1 2020 gross revenue was C$7.65 million, with cost of goods sold of C$7.05 million, resulting in gross profits of C$605,150. Operating and other operating expenses for the three months ended March 31, 2020 were C$5.24 million.
The Company raised C$1.72 million through share subscriptions received for the issuance of units at C$0.28 and received C$309,000 in proceeds from the exercise of warrants.
The Company ended Q1 2020 with C$2.1 million in cash.
Dominant Online Customer Acquisition Strategy
The Company credits its success to its’ online customer acquisition strategy, which is capitalizing on the strong consumer demand for natural health solutions, resulting in an interim record number of customer acquisitions for the Nature’s Exclusive brand, as well as, new customers for the immune support category introduced in March 2020.
The Company's customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature's Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.
The company said it plans to follow a similar rollout strategy as it did in the US market in Europe.
PEMTF acquired 102,844 new customers during the six-month period ending June 30, 2020.
This record number of customers acquired can be attributed to the Company's increased marketing efforts of its Nature's Exclusive brand, as well as a successful scaling of the Company's supply chain, and its ability to respond to market demand in the midst of a global pandemic through the introduction of new and relevant products.
Market Outlook:
“The hemp-CBD market alone is estimated to hit $22 billion by 2022.”
– The Brightfield Group
Boomers and millennials alike are buzzing about three letters - CBD.
CBD has become very popular in recent years and is considered one of the hottest new health and wellness trends.
It is a natural compound found in cannabis and hemp and does not cause a high like the compound THC. Changes to state and federal laws have led to a rise in the production of CBD-infused products.
More and more consumers are realizing the medicinal benefits of this cannabidiol.
CBD oil is said to treat a wide variety of health problems, including: pain, epileptic seizures, anxiety disorders and depression, insomnia, stress, skin conditions, etc.
According to Grand View Research, by 2027, adult-use medicinal cannabis is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.
35% of U.S. adults say they are not familiar with CBD, while another 50% say they are aware of it but do not use it.
Do you know what this means? It means there is still a significant chunk of America that could be on its way to using CBD. The market potential is a monster.
Hemp CBD is one of the fastest-growing markets in a generation with sales projected to reach into the billions. The Hemp Business Journal has predicted that the market for CBD will grow from $390 million in 2018 to approximately $1.3 billion by 2022.
CBD is seeing monumental demand in Europe!
In Europe alone, the CBD market is on course to grow 400% over the next four years, according to the Brightfield Group.
According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.
THE PSYCHEDELIC MEDICINE OPPORTUNITY
The new buzzed topic is psychedelic medicine and this "mush rush" ... this "shroom boom" could send early players in the space soaring.
Psilocybin, or better known as medicinal mushrooms, could be the key to treating many mental disorders in the world. This includes depression, anxiety, and even addiction.
Can you imagine big pharma jumping all over this?
GW Pharmaceuticals not long ago became well known for its popular cannabidiol (CBD)-based drug, Epidiolex. It is the first FDA approved medication made from cannabis and has produced millions upon millions in revenue for the company.
Magic mushrooms in fact are the safest “recreational” drug to take and those who take them are the most sensible and well prepared, according to the 2017 Global Drug Survey.
Out of almost 10,000 people who took them, only 0.2% needed emergency medical treatment.
Ongoing clinical trials are discovering the uses of psilocybin in the treatment of addiction and other mental health problems.
Johns Hopkins University is the leading psychedelic research institution in the U.S., and among the few leading groups worldwide.
Its publication on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide!
The University began clinical trials on the potential positive effects of the drug when it comes to aiding treatment-averse depression, addiction, and anxiety.
The results were so promising that the institution published an article arguing that psilocybin should be considered a Schedule 5 drug!
At the Center for Psychedelic and Consciousness Research, researchers will now focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health.
Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use in people with major depression.
Recent Developments:
Thoughtful Brands Aquires E-Commerce Platform That Has Facilitated Over $200 Million in Consumer Transactions
Thoughtful Brands Enters into Letters of Intent to Consider Acquisitions of Golden Path and Wild Mariposa
The Bottom Line:
PEMTF is trading at mere pennies yet has a narrative that reads like a big board story.
Just look at some comparatives in the arena to see what substantial growth potential the company has:
The company is poised to take its winning model from America to Europe and is aiming to become a CBD leader on two continents!
An entrance into the psilocybin space could also be a massive opportunity for the company to capitalize on the Mush Rush. Medicinal mushrooms could be the key to treating depression, anxiety, addiction, and even Alzheimer's Disease.
Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.
As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.
At these share prices PEMTF may be a ground-floor situation to keep a close eye on!
PEMTF may be one of 2020's biggest secrets trading on Wall Street headed towards major recognition soon!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)